Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed competition impacts on the company's primary product [3][5]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical and its executives made false or misleading statements regarding the demand for their primary product, the Lapiplasty 3D Bunion Correction System, and failed to disclose competitive pressures affecting revenue [5]. - Following a press release on May 7, 2024, the company lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million, indicating significant revenue decline [6]. - The stock price of Treace Medical fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, following the announcement of the lowered revenue guidance [7]. Group 2: Legal Proceedings - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, are encouraged to discuss their legal rights and options, with a deadline of June 10, 2025, to seek the role of lead plaintiff in the federal securities class action [2][3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Treace's conduct [9].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Financial Performance - Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - Following this announcement, Treace Medical's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]

Group 1 - The Rosen Law Firm is reminding purchasers of Treace Medical Concepts, Inc. securities of the June 10, 2025 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Treace Medical securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the Class Period, Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [5] - The lawsuit asserts that the positive statements made by Treace Medical about its business and prospects were materially misleading [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms in securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Treace Medical Concepts, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Treace Medical securities is from May 8, 2023, to May 7, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 10, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors [3] Group 3: Case Allegations - The lawsuit alleges that Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [4] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [4] - The lawsuit asserts that the positive statements made by the defendants about the company's business and prospects were materially misleading [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from May 8, 2023, to May 7, 2024 [1] Allegations - The complaint alleges that competition negatively affected the demand and utilization of Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty" [1] - As a result of the competition, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [1] - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1] Class Action Details - Shareholders who purchased shares of TMCI during the specified class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2] - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [2] - There is no cost or obligation for shareholders to participate in the case [2] Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Group 1 - The Rosen Law Firm is reminding purchasers of Treace Medical Concepts, Inc. securities of the June 10, 2025 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Treace Medical securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the Class Period, Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [5] - The lawsuit asserts that the positive statements made by Treace Medical about its business and prospects were materially misleading and lacked a reasonable basis [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been recognized as a leader in the field of securities class action litigation [4]

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [2][3]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical failed to disclose competition's impact on the demand and utilization of its primary product [2] - As a result of these undisclosed factors, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Following the revelation of these issues, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action and must file their papers by June 10, 2025, to serve as lead plaintiff [3] - The lead plaintiff represents other class members in directing the litigation, but participation is not required to be eligible for recovery [3] Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit alleging misleading statements and failure to disclose critical information that affected the company's stock value during the specified class period [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants' positive statements regarding the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who incurred losses due to false or misleading statements that led to artificial inflation of the company's stock [3].

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Group 1: Allegations and Impact - The lawsuit claims that competition negatively affected the demand and utilization of the Lapiplasty system [3]. - As a result of the competitive pressure, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [3]. - The defendants' positive statements about the company's business and prospects were allegedly misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased TMCI shares during this period are encouraged to register for the class action, with a deadline set for June 10, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4].